N/A N=14 A Study of Breastfeeding in Buprenorphine Maintained Women
Opioid Dependency
Primary: Maternal Plasma Concentrations of Buprenorphine — 1.2; 1.7; 2.0; 2.4 ug/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Leukemia · Amyloidosis
Primary: Hematologic Response Rate — 2; 4; 8; 9 participants
Phase 2 N=128 E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Progression Free Survival (PFS) at 12 Weeks — 46.9; 31.6; 21.1; 19.2 Percentage of participants
Phase 3 N=240 Effect of Self-Management on Improving Sleep Apnea Outcomes
Sleep Apnea Syndromes
Primary: CPAP Adherence — 2.8; 3.9 hours per night — p=0.001
Phase 4 N=52 Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction
Heart Failure
Primary: Exercise Treadmill Time — 621; 580; 624; 579 seconds — p=0.90
Phase 2 N=30 Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Breast Cancer
Primary: Proportion of Patients Experiencing Grade 3 or 4 Diarrhea as Measured by NCI CTCAE v3.0 — 43 percentage of patients
Phase 1 N=50 Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)
Immune Thrombocytopenia Purpura
Primary: Number of Participants Experiencing an Adverse Event — 2; 2; 4; 1 Participants
N/A N=408 A Study to Evaluate the Safety Profile of an e-Vapour Product
Healthy Volunteers
Primary: Adverse Events — 1.60; 0.79 percentage of adverse events
Phase 2 N=31 Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate — 25 Participants
N/A N=722 Swiss Army Physical Fitness Training
Wounds and Injuries · Physical Activity · Mood (Psychological Function)
Primary: Number of Participants With Injuries — 184; 172 participants with injuries
Phase 4 N=33 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population
Opioid Dependence
Primary: Overall Intervention Preference As Assessed by Participants — 54.84; 45.16 percentage of participants — p=>0.5000
Phase 3 N=803 Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis — -0.3; -50.2; -52.7; -1.6 percent change…
Phase 3 N=295 A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years
Epilepsy, Partial Seizures
Primary: Log-Transformed 28-Day Seizure Rate For All Partial Onset Seizures During Baseline Phase — 3.27; 3.19; 3.18 Seizures per 28 days
N/A N=1,069 Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
HIV Infections
Primary: Measurement of Acceptance Rate of PrEP — 921; 557 Participants
N/A N=30 Effectiveness of Preoperative Surgical Scrubbing Using Clorhexidine Digluconate and Parachlorometaxylenol (ECP)
Skin Diseases · Surgical Site Infection
Primary: Change in the Release of Skin Flora From the Hands From Baseline to 5 Minutes After Disinfection by Surgical Scrubbing (Time Frame- "Baseline and 5 Minutes"). — 3.96…